£295 / $515 / €370
Carl Zeiss Meditec AG (CZM) is a leading medical technology company that has been active in the optical sector for more than 160 years. The company operates under three business units – the Ophthalmic Systems and Surgical Ophthalmology units comprise the company’s activities in the ophthalmic market; Ophthalmic Systems includes medical laser and diagnostic systems, and Surgical Ophthalmology combines the company’s activities in the field of intraocular lenses (IOLs) and consumables. The third business unit is Microsurgery, which comprises CZM’s activities in the field of neuro, ear, nose and throat surgery (surgical microscopes), surgical visualisation solutions and intraoperative radiation therapy.
Between 2005 and 2007, three strategic acquisitions played a key part in expanding CZM’s activities. In 2005, the purchase of Ioltech added a range of IOLs and consumables to CZM's product portfolio; Carl Zeiss Surgical, the world's leading provider of surgical microscopes, added visualisation solutions for ophthalmic, neuro and ENT surgery to the CZM range in 2006; and in 2007, the acquisition of Acri.Tec in Germany expanded CZM's offering in the ophthalmic surgery segment.
CZM is based in Jena, Germany, and has principal subsidiaries in Germany, the US, Japan, Spain and France. In the fiscal year ended 30th September 2009, the company generated revenues of EUR640.1 million and employed more than 2,140 people.
Sixty-five per cent of CZM shares are held by Carl Zeiss, a manufacturer of optical and opto-electronics systems. The remaining 35% of the shares are in free float.
This company report provides
Investigates the company’s aims and its areas of focus
Core product areas, key brands, product approvals and launches
|Research and Development
Manufacturing and Distribution
Mergers, Acquisitions, Minority Investments and Divestments
Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.